Soil partice-size distribution. by Yonggang Huang (223155)

Subjects:

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size. by Francesca Catto (21253435)

“…However, there is only a minimal effect on decreasing plaque size. (C) Short-term-treatment with a high dose of netoglitazone reveals a significant reduction in plaque size, especially observed in the hippocampus, striatum, thalamus, hypothalamus, midbrain, and hindbrain. …”

The linearly decreasing convergence factor a. by Junhao Wei (6816803)

Comparison of the Non-healed but Improved DUs Based on Initial Wound Area Size in 2022 vs. 2023. by Heba Tallah Mohammed (2822432)

Subjects:

Comparison of the Non-healed but Improved PIs Based on Initial Wound Area Size in 2022 vs. 2023. by Heba Tallah Mohammed (2822432)

Subjects:

JP4-039 decreases mitochondrial ROS in human coronary artery endothelial cells <i>in vitro.</i> by Rayane Brinck Teixeira (6676529)

Supplementary Material for: Longitudinal Decrease in Left Ventricular Size with Age: Impact on Mortality and Cardiovascular Hospitalization by figshare admin karger (2628495)

“…This study investigated clinical characteristics and outcomes associated with longitudinal decreases in LV size in this population. Methods: We analyzed echocardiographic data from 6,232 adults with normal baseline left ventricular end-diastolic diameter (LVEDD), with a mean interval of 4.8 years between baseline and follow-up echocardiograms. …”

Enrichment analysis of genes from the significant MS module. by Lai Jiang (2401513)

Subjects:

Group-based descriptive statistics and effect sizes. by Murat Tutar (22250461)

Subjects:

Transition probabilities and class sizes for three-step LTA model (N = 432). by Carolin Oetzmann (11397968)

Subjects:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Particle size distribution curve. by Quan Shen (37564)

Subjects:

Overview of the WeARTolerance program. by Ana Beato (20489933)

Subjects:

Based on our time series data(first from the left), the visualizations of linear residual predictions under different decimation rates (next three) show that as the decimation rate... by Hua Huo (1818133)

DataSheet1_Pharmacological inhibition of receptor protein tyrosine phosphatase β/ζ decreases Aβ plaques and neuroinflammation in the hippocampus of APP/PS1 mice.docx by Teresa Fontán-Baselga (20392470)

“…In addition, we observed a significant decrease in the number and size of astrocytes in both sexes and in the number of microglial cells in a sex-dependent manner. …”

Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

Arctigenin decreased proliferation in colorectal cancer cells with no significant effect on normal cells. by Xiang-Fan Chen (13932983)

iKIR score decreases protection associated with protective class II genotypes in T1D. by Laura Mora-Bitria (20477525)